Research programme: riminophenazine tuberculosis therapies - Materia Medica/TB Alliance
Latest Information Update: 16 Jul 2016
At a glance
- Originator Institute of Materia Medica
- Developer Global Alliance for TB Drug Development; Institute of Materia Medica
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Tuberculosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Tuberculosis in China
- 02 Feb 2007 Preclinical trials in Tuberculosis in China (unspecified route)